Nigella Sativa Seed Oil Shows Early Promise in Modulating Gut Microbiome

What's new

Researchers conducted a pilot study to explore how oral supplementation with Nigella sativa seed oil (NSSO), which contains the bioactive compound thymoquinone (TQ), influences the gut microbiome in healthy individuals. While overall microbial diversity remained stable, the study identified specific changes in the abundance of certain gut bacteria. It also confirmed that thymoquinone and its metabolites are detectable in urine following repeated NSSO consumption [1]. These preliminary findings suggest NSSO's potential to selectively modify gut microbiota and lay the groundwork for more extensive research, particularly in areas where gut health is critical, such as perioperative care in gastrointestinal surgery.

The science behind it

The gut microbiome, a complex ecosystem of microorganisms, plays crucial roles in human health, including digestion, immune regulation, and nutrient production. Its composition and diversity are linked to various health outcomes, and imbalances (dysbiosis) are associated with conditions like inflammatory bowel disease and metabolic disorders. Nigella sativa (black seed) and its oil have long been recognized for their antimicrobial and immunomodulatory properties, primarily attributed to thymoquinone [1].

This prospective, randomized, open-label pilot study involved eight healthy adults. Four participants received NSSO capsules (containing TQ) three times daily for 20 days, while the other four served as controls. Fecal samples were collected at five time points for 16S rRNA gene sequencing to analyze changes in gut microbial composition. Urine samples were also analyzed for TQ and its metabolites using Gas Chromatography Mass Spectrometry (GC-MS) [1].

Although the study did not observe significant changes in overall alpha or beta diversity (measures of microbial diversity within and between samples, respectively), indicating a stable microbiome composition, it did identify specific bacterial taxa that either increased or decreased in abundance within the treatment group. For instance, Mediterraneibacter lactaris showed a significant increase, while Terrisporobacter mayombei significantly decreased. The detection of TQ and/or TQ-H₂ in the urine of participants receiving NSSO confirmed systemic absorption and metabolism of the compound following oral intake [1].

What it means in practice

This pilot study provides early evidence that Nigella sativa seed oil can induce specific, albeit subtle, changes in the gut microbiome of healthy individuals. The ability to modulate the gut microbiota could have implications for various health conditions, especially those where gut health is compromised or needs support. For example, maintaining a healthy gut microbiome is considered important in gastrointestinal surgery, where factors like fasting, bowel preparation, and antibiotics can disrupt the microbial balance. A stable and diverse microbiome is associated with better resistance to disturbances and potentially improved surgical outcomes, such as reduced risk of anastomotic leakage [1].

While this study focused on healthy volunteers, the findings could inform future research into NSSO's potential as a dietary intervention to support gut health in clinical settings. The confirmed detectability of thymoquinone in urine after oral intake is also a crucial step, demonstrating that the active compound is absorbed and metabolized by the body, which is essential for its potential therapeutic effects [1].

Caveats

It is important to acknowledge the significant limitations of this study. Firstly, it was a small-scale pilot study involving only eight healthy adults, with a very limited sample size of four participants in each group. This small number severely restricts the generalizability of the findings and the statistical power to detect subtle changes. Secondly, the study was open-label, meaning both participants and researchers knew who was receiving the treatment, which could introduce bias. There was also no placebo control group, making it difficult to definitively attribute observed changes solely to NSSO [1].

Furthermore, while specific bacterial changes were noted, the overall alpha and beta diversity remained stable, suggesting that NSSO's impact on the broader microbial community might be limited or require longer intervention periods or different dosages to become more pronounced. The study also did not permit pharmacokinetic conclusions regarding TQ metabolism. These findings are considered preliminary and serve primarily to guide the design of future, more robust, blinded, placebo-controlled, and diet-controlled studies with larger cohorts [1].

Source: https://www.nature.com/articles/s41598-026-69567-3